Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Hemorrhage | 10 | 2022 | 198 | 1.840 |
Why?
|
| Deferoxamine | 4 | 2022 | 45 | 1.260 |
Why?
|
| Endovascular Procedures | 11 | 2017 | 366 | 0.820 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2017 | 296 | 0.800 |
Why?
|
| Fibrinolytic Agents | 11 | 2017 | 377 | 0.650 |
Why?
|
| Thrombolytic Therapy | 8 | 2017 | 233 | 0.640 |
Why?
|
| Stroke | 13 | 2017 | 2161 | 0.620 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 497 | 0.560 |
Why?
|
| Nicardipine | 3 | 2020 | 21 | 0.550 |
Why?
|
| Brain Ischemia | 6 | 2017 | 665 | 0.450 |
Why?
|
| Hematoma | 3 | 2021 | 47 | 0.430 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2021 | 348 | 0.430 |
Why?
|
| Cerebral Angiography | 8 | 2015 | 151 | 0.410 |
Why?
|
| Treatment Outcome | 20 | 2022 | 7028 | 0.390 |
Why?
|
| Collateral Circulation | 3 | 2015 | 34 | 0.390 |
Why?
|
| Medical Futility | 3 | 2022 | 31 | 0.380 |
Why?
|
| Blood Pressure | 4 | 2020 | 1447 | 0.350 |
Why?
|
| Bile Duct Neoplasms | 2 | 2020 | 39 | 0.340 |
Why?
|
| Cholestasis | 2 | 2020 | 90 | 0.330 |
Why?
|
| Pancreatitis | 3 | 2021 | 279 | 0.320 |
Why?
|
| Research Design | 4 | 2022 | 729 | 0.290 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2015 | 134 | 0.270 |
Why?
|
| Aged | 21 | 2021 | 14842 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 239 | 0.240 |
Why?
|
| Patient Selection | 2 | 2021 | 592 | 0.240 |
Why?
|
| Middle Aged | 22 | 2021 | 21119 | 0.230 |
Why?
|
| Disease Progression | 3 | 2021 | 1037 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1737 | 0.230 |
Why?
|
| Humans | 31 | 2022 | 68525 | 0.210 |
Why?
|
| Thrombectomy | 2 | 2014 | 238 | 0.200 |
Why?
|
| Drainage | 2 | 2020 | 133 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Sphincter of Oddi | 1 | 2021 | 51 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2323 | 0.190 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2020 | 4 | 0.190 |
Why?
|
| Bias | 1 | 2021 | 148 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 107 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 253 | 0.180 |
Why?
|
| Male | 22 | 2021 | 37281 | 0.180 |
Why?
|
| Female | 22 | 2021 | 38015 | 0.170 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 31 | 0.170 |
Why?
|
| Indomethacin | 2 | 2016 | 107 | 0.170 |
Why?
|
| Internationality | 1 | 2019 | 74 | 0.170 |
Why?
|
| Carotid Artery, Internal | 2 | 2015 | 85 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 4843 | 0.160 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 83 | 0.160 |
Why?
|
| Acute Disease | 4 | 2022 | 658 | 0.160 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2015 | 105 | 0.160 |
Why?
|
| Infusions, Intravenous | 4 | 2021 | 334 | 0.150 |
Why?
|
| Reperfusion | 2 | 2014 | 78 | 0.150 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.150 |
Why?
|
| Disease Management | 2 | 2015 | 248 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1851 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 951 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2015 | 219 | 0.130 |
Why?
|
| Adult | 13 | 2021 | 21375 | 0.130 |
Why?
|
| Young Adult | 8 | 2021 | 5708 | 0.130 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2014 | 28 | 0.120 |
Why?
|
| Cerebral Revascularization | 1 | 2014 | 45 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2017 | 346 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 296 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2014 | 86 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 329 | 0.110 |
Why?
|
| Stents | 1 | 2016 | 657 | 0.100 |
Why?
|
| Disability Evaluation | 3 | 2020 | 298 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2020 | 3702 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 929 | 0.090 |
Why?
|
| Hypertension | 1 | 2018 | 1531 | 0.080 |
Why?
|
| United States | 5 | 2020 | 7335 | 0.080 |
Why?
|
| Adolescent | 5 | 2021 | 8903 | 0.080 |
Why?
|
| Quality of Life | 1 | 2015 | 1515 | 0.070 |
Why?
|
| Administration, Rectal | 2 | 2016 | 26 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 848 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2020 | 506 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 563 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2021 | 24 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.050 |
Why?
|
| Taiwan | 1 | 2020 | 20 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 2004 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2020 | 23 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 216 | 0.050 |
Why?
|
| Japan | 1 | 2020 | 68 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 67 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 249 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 110 | 0.050 |
Why?
|
| North America | 1 | 2020 | 111 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2020 | 14 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2020 | 108 | 0.050 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2021 | 79 | 0.050 |
Why?
|
| China | 1 | 2020 | 138 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 303 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3256 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 89 | 0.050 |
Why?
|
| Manometry | 1 | 2021 | 276 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 1425 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 880 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 2356 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 177 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5719 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2022 | 1745 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 36 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 149 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 186 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 105 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 195 | 0.040 |
Why?
|
| Health Resources | 1 | 2017 | 76 | 0.040 |
Why?
|
| Cost Savings | 1 | 2017 | 110 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 266 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 235 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2016 | 13 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 27 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 68 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 16 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 977 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 711 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 503 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 30 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 57 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 84 | 0.030 |
Why?
|
| Case Management | 1 | 2013 | 46 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 193 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 242 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 181 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 249 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 689 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2014 | 320 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1465 | 0.020 |
Why?
|